depression
Instructed patient that it is not uncommon to experience significant stress, anxiety or depression when receiving your LVAD or becoming a caregiver for an LVAD recipient. There have been a lot of changes in your body and your life recently. There are many different causes of mental health issues, many of which are not under your control. If you are experiencing symptoms of depression or anxiety, it is not a bad thing to ask for help. There are many new medications and treatments available to help you feel better. Sometimes mental health issues are not recognized by the person who is affected. We have provided this tool to help you or a loved one identify when you may need to ask for help. Understanding was verbalized.
Rn instructed caregiver , about complications about patient with cerebral palsy , muscle weakness, muscle spasticity and coordination problems can contribute to a number of complications either including, contracture, malnutrition. Swallowing or feeding problems can make it difficult for someone who has cerebral palsy,mental health conditions. People with cerebral palsy might have mental health conditions, such as depression. Social isolation and the challenges of coping with disabilities can contribute to depression. Caregiver verbalized.
Patient instructed on new medication Abilify. Abilify is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar I disorder (manic depression). It is also used together with other medicines to treat major depressive disorder in adults. May be taken with or without food, take at the same time daily. Do not stop abruptly or change dosage without consulting prescriber. Notify prescriber if unusual or bothersome side effects occur.
Instructed to contact your doctor or go to your local hospital or emergency room, if you are in an immediate serious despression crisis.
Instructed in new medication Amoxicillin and in S/E such as lethargy, hallucinations, seizures, anxiety, confusion, agitation, depression, dizziness, fatigue, nausea, vomiting, diarrhea, glossitis, stomatitis, gastritis, abdominal pain, enterocolitis, pseudomembranous colitis, black tongue, interstitial nephritis, nephropathy, vaginitis, anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, hemolytic anemia, agranulocytosis, hypersensitivity reactions, anaphylaxis, and overgrowth of nonsusceptible organisms. Notify MD if rash, fever, or chills develop. A rash is the most common allergic reaction, especially if allopurinol is also being taken.
Instructed in new medication Toprol and in S/E such as fatigue, dizziness, depression, bradycardia, hypotension, heart failure, AV block, nausea, diarrhea, dyspnea and rash.
Instructed in new medication Sulfaprim and in S/E such as headache, mental depression, aseptic meningitis, tinnitus, apathy, seizures, hallucinations, ataxia, nervousness, fatigue, vertigo, insomnia, thrombophlebitis, nausea, vomiting, diarrhea, abdominal pain, anorexia, stomatitis, pancreatitis, pseudomembranous colitis, toxic nephrosis with oliguria and anuria, crystalluria, hematuria, interstitial nephritis, agranulocytosis, aplastic anemia, megaloblastic anemia, thrombocytopenia, leukopenia, hemolytic anemia, jaundice, hepatic necrosis, arthralgia, myalgia, muscle weakness, pulmonary infiltrates, erythema multiforme, Stevens-Johnson syndrome, generalized skin eruption, toxic epidermal necrolysis, exfoliative dermatitis, photosensitivity, urticaria, pruritus, hypersensitivity reactions, serum sickness, drug fever and anaphylaxis.
Instructed in new medication Sinemet and in S/E such as choreiform, dystonic, dyskinetic movements, involuntary grimacing, head movements, myoclonic body jerks, ataxia, tremor, muscle twitching, bradykinetic episodes, psychiatric disturbances, anxiety, disturbing dreams, euphoria, malaise, fatigue, severe depression, suicidal tendencies, dementia, delirium, hallucinations (may necessitate reduction or withdrawal of drug), confusion, insomnia, agitation, orthostatic hypotension, cardiac irregularities, phlebitis, blepharospasm, blurred vision, diplopia, mydriasis or miosis, oculogyric crises, excessive salivation, dry mouth, bitter taste, nausea, vomiting, anorexia, constipation, flatulence, diarrhea, abdominal pain, urinary frequency, urine retention, urinary incontinence, darkened urine, priapism, hemolytic anemia, thrombocytopenia, leukopenia, agranulocytosis, hepatotoxicity, weight loss (may occur at start of therapy), hiccups, hyperventilation, and dark perspiration.
Instructed in S/E of oxygen therapy such as respiratory depression, collapse lung, irritation of airway mucosa, oxygen toxicity, local skin irritation.
Instructed in new medication Wellbutrin to manage depression. In addition, warned of possible S/E such as headache, seizures, anxiety, confusion, delusions, euphoria, hostility, impaired sleep quality, insomnia, sedation, tremor, akinesia, akathisia, agitation, dizziness, fatigue, syncope, fever, arrhythmias, hypertension, hypotension, palpitations, tachycardia, auditory disturbances, blurred vision, dry mouth, taste disturbance, increased appetite, constipation, dyspepsia, nausea, vomiting, anorexia, diarrhea, impotence, menstrual complaints, urinary frequency, urine retention, weight loss, weight gain, arthritis, pruritus, rash, cutaneous temperature disturbance, excessive diaphoresis, chills and decreased libido. Advised to avoid prolonged sun exposure and to use sun block.